Side Effects and Research Progress of Immune Checkpoint Inhibitors

Yichen Li

doi:10.62051/wr78rk47

Authors

Yichen Li

DOI:

https://doi.org/10.62051/wr78rk47

Keywords:

ICIs; skin-related adverse effects; checkpoint inhibitor pneumonia; thyroid-related adverse effects; gastrointestinal-related adverse effects.

Abstract

Immune checkpoint inhibitor (ICI) is a new type of tumor treatment drug, also known as immunotherapy drug. They target "checkpoint" molecules in the body's immune system that prevent immune cells from attacking cancer cells. They target "checkpoint" molecules in the body's immune system that prevent immune cells from attacking cancer cells. The use of immune checkpoint inhibitors can help control or treat certain types of cancer by promoting the restoration of inactivated immune cells and enhancing the immune system's ability to attack. -This article focuses on skin reactions, immune pneumonitis, and adverse reactions in the thyroid and digestive tract. Through the analysis of recent relevant research, this question summarizes several different side effects, their causes and treatments. Although there are many treatments to deal with the side effects of this drug, it is important to note that the side effects of this drug are not always well understood. There are many treatments to deal with the related side effects, these side effects are still a barrier to the current use of ICIs. Future development directions should focus more on the development of ICIs. directions should focus more on the development of new targets, optimization of drug pharmacokinetics, and alleviation of side effects caused by ICIs.

Downloads

Download data is not yet available.

References

Jiang Pei, Yao Weirong, Shen Qinglin. Current status and challenges in the treatment of immune checkpoint inhibitors in triple-negative breast cancer. Chinese Journal of Cancer Prevention and Control, 2023, 30 (17): 1062 - 1068.

Wang LL, Patel G, Chiesa-Fuxench ZC, et a1. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol, 2018, 154 (9): 1057 - 1061.

Puzanov I, Diab A, Abdallah K, et a1. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 2017, 5 (1):95.

Tattersall IW, Leventhal JS. cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. yale J Biol Med, 2020, 93 (1): 123 - 132.

Cheng Haixing, Zhang Daojun, Hao Fei. Skin adverse reactions associated with immune checkpoint inhibitors. Chinese Journal of Dermatology and Venereology, 2023, 37 (6): 727 - 731.

Phillips GS, Freites-Martinez A, Wu J, et a1. Clinical characterization of. immunotherapy-related pruritus among patients seen in 2 oncodermatology chinics. JAMA Dermatol, 2019, 155 (2): 249 - 251.

M D B, S G P, N A G, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Annals of oncology: official journal of the European Society for Medical Oncology, 2021, 32 (6).

Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017, 35 (7): 709.

HuangYF, FanHY, Lin, et al. Riskofimmune-relat-edpneumonitisforPD1/PD-L1 inhibitors: systematic review and network meta-analysis. Cancer Med, 2019, 8 (5): 2664.

Wang WX, Wang Q, Xu CW, et al. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. ThoracCancer, 2022, 13 (23): 3420.

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018, 378 (2): 158 - 168.

Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. Expert Opin Drug Saf, 2021. 20 (5): 537 - 547.

Pozzessere C, Bouchaab H, Jumeau R, et al. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. ERJ Open Res, 2020, 6 (1): 165.

Li Hong-Min, Zhao Yong-Cai, GUO Peng, et al. Progress of immune checkpoint inhibitor-associated thyrotoxicity. Modern Oncology Medicine, 2023, 31 (8):1568 - 1572.

Ascierto PA, Vecchio MD, Robert C, et a1. ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomized, double-blind, multicentre, phase 3 trial. Lancet Oncol, 2017, 18 (5): 611 - 622.

Barroso SR, Barry WT, Garrido AC, et a1. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol, 2018, 4 (2): 173 - 182.

Antonelh A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer. Expert Rev Anticancer Ther, 2018, 18 (2): 149 - 159.

Kotwal A, Gustafson MP, Bornschlegl S, et a1. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid, 2020, 30 (10): 1440 - 1450.

Zhang Y, Garofano F, Wu XL, et a1. Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics. Invest New Drugs, 2020, 38 (6): 1717 - 1729.

Dong MY,Peng WY. Immune checkpoint inhibitor-associated gastrointestinal toxicity. Chinese Journal of Clinical Physicians, 2023, 51 (10): 1140 - 1144.